We are live on ! Find out more
PBPIA

Pivotal bioVenture Partners Investment Advisor Portfolio holdings

AUM $280M
1-Year Est. Return 181.4%
This Fund
S&P 500
This Quarter Est. Return
-5.84%
1 Year Est. Return
+181.4%
3 Year Est. Return
+730.97%
5 Year Est. Return
+1,157.4%
10 Year Est. Return
–
AUM
$211M
AUM Growth
-$27.8M
Cap. Flow
+$7.4M
Cap. Flow %
3.5%
Top 10 Hldgs %
99.11%
Holding
11
New
1
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
VIGL
Vigil Neuroscience
VIGL
+$7.4M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$108M 51.15%
852,708
– –
PCVX icon
2
Vaxcyte
PCVX
$8.93B
$26.8M 12.7%
1,111,485
– –
RLYB icon
3
Rallybio
RLYB
$86.7M
$15.9M 7.5%
283,914
– –
FUSN
4
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$12.4M 5.88%
1,598,377
– –
EXAI
5
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$11.1M 5.26%
772,285
– –
ARQT icon
6
Arcutis Biotherapeutics
ARQT
$3.27B
$11M 5.19%
569,041
– –
AKUS
7
DELISTED
Akouos Inc
AKUS
$8.52M 4.03%
1,794,088
– –
INZY
8
DELISTED
Inozyme Pharma
INZY
$6.51M 3.08%
1,591,154
– –
BOLT icon
9
Bolt Biotherapeutics
BOLT
$6.46M
$5.18M 2.45%
94,573
– –
VIGL
10
DELISTED
Vigil Neuroscience
VIGL
$3.94M 1.86%
+560,595
New +$7.4M
ALGS icon
11
Aligos Therapeutics
ALGS
$45.2M
$1.89M 0.89%
35,062
– –

Similar funds

HCM
Hall Capital Management Barrington, Rhode Island $280M AUM 14.82% 1-Year Est. Return
OFCM
One Fin Capital Management San Francisco, California $280M AUM 49.87% 1-Year Est. Return
NCM
NCM Capital Management Ramsey, New Jersey $279M AUM 26.47% 1-Year Est. Return
CCC
Compass Capital Corp Braintree, Massachusetts $279M AUM 28.36% 1-Year Est. Return
PHC
Panoramic Hills Capital Road Town $280M AUM
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
SL
SOF Ltd George Town, Cayman Islands $279M AUM 6.12% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor's Q1 2022 Portfolio in Review

As of Q1 2022, Pivotal bioVenture Partners Investment Advisor held 11 positions worth $211M, down 12% from $239M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Pivotal bioVenture Partners Investment Advisor deployed $7.4M of net new capital in Q1 2022, opening 1 new position. Its largest new stake was Vigil Neuroscience: 560,595 shares worth $3.94M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Pivotal bioVenture Partners Investment Advisor's largest Q1 2022 buy was Vigil Neuroscience: 560,595 shares worth $3.94M.
  • Pivotal bioVenture Partners Investment Advisor's ten largest holdings make up 99% of its $211M portfolio in Q1 2022.
  • Pivotal bioVenture Partners Investment Advisor opened 1 new position and closed 0 in Q1 2022.
  • Pivotal bioVenture Partners Investment Advisor's portfolio value fell 12% quarter-over-quarter to $211M.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q1 2022, filed 13 May 2022.